Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
investigational drug |
| gptkbp:administeredBy |
once weekly
|
| gptkbp:alternativeName |
TransCon CNP (Ascendis Pharma)
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2024)
|
| gptkbp:developedBy |
gptkb:Ascendis_Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
TransCon CNP
|
| gptkbp:indication |
pediatric achondroplasia
|
| gptkbp:intendedUse |
treatment of achondroplasia
|
| gptkbp:mechanismOfAction |
C-type natriuretic peptide (CNP) prodrug
|
| gptkbp:prodrugOf |
gptkb:CNP
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:status |
investigational
|
| gptkbp:target |
NPR-B receptor
|
| gptkbp:bfsParent |
gptkb:Ascendis_Pharma
|
| gptkbp:bfsLayer |
8
|